Better biologics faster, via ML-guided multi-parameter optimization and de novo design
Jorge Condenamed it in 1 interview“On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences.” — a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside (a16z Live, 2021)
Julie Yoonamed it in 1 interview“On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences.” — a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside (a16z Live, 2021)
Vineeta Agarwalanamed it in 1 interview“On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences.” — a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside (a16z Live, 2021)| a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside | Jorge Conde, Julie Yoo, Vineeta Agarwala | a16z Live | 2021-03-18 | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences. The conversation covers the growing role of artificial intelligence and machine learning in drug development and specifically in biologics and protein therapeutics. |